KIRKLAND, Wash.--(BUSINESS WIRE)--Prevencio, Inc. today announces the presentation of data acquired in patients with spinal cord injury demonstrating that its Artificial Intelligence (AI)-driven HART CVE blood test is useful, low risk and as accurate as currently used cardiac risk imaging tests that require radiation exposure. Researchers and clinicians from the Veteran’s Administration in the Bronx, New York, collaborated to test their population with spinal cord injury for risk of major cardiac events, including heart attack, stroke, and cardiac death.
“Spinal cord injury patients have extremely sedentary lifestyles and, consequently, cardiac disease is highly prevalent,” said William A. Bauman, M.D., Director of the Department of Veterans Affairs Rehabilitation Research & Development Service’s National Center for the Medical Consequences of Spinal Cord Injury. “We were pleased to find that Prevencio’s multiple protein HART CVE blood test proved to be a highly useful clinical tool demonstrating a relationship with coronary artery calcium scores and the Framingham scoring system to predict a cardiac event. This preliminary finding is important because our goal was to identify an accurate test for assessment of cardiac risk for patients with spinal cord injury which can be easily obtained and does not require exposure to radiation.”
In the general population, HART CVE had previously been reported to be more accurate (86% AUC accuracy) than standard-of-care stress tests (52% AUC accuracy) and coronary artery calcium scores (~60% AUC accuracy).
“Prevencio is grateful to work with Dr. Bauman and his team of researchers to demonstrate HART CVE’s accuracy, low-cost, low-risk, and radiation-free blood test to assess cardiac risk for this patient group that is at elevated risk for atherosclerotic vascular disease,” said Rhonda Rhyne, President and Chief Executive Officer of Prevencio.
In the U.S., there are an estimated 291,000 people living with spinal cord injuries, about 40,000 of whom are veterans. These individuals cannot walk on a treadmill to have their hearts stress tested by traditional means, and physicians have had to rely on risk scores or imaging procedures that require radiation to assess the risk of a cardiac event.
Prevencio recently launched for patient use its two lead tests, HART CVE (for one-year risk of heart attack, stroke, or cardiac death) and HART CADhs (for obstructive heart disease diagnosis) and is applying for a Veteran’s Administration contract. For additional information, visit Prevencio, Inc.
About Prevencio HART Tests: Powered by AI, Prevencio is revolutionizing blood tests for cardiovascular disease and custom diagnostics. Employing this novel approach, the Company has developed seven blood tests that significantly improve diagnosis and risk assessment for a variety of heart and blood vessel-related complications.
Our three lead tests include:
- HART CVE™ – 1-year risk of heart attack, stroke, or cardiac death
- HART CADhs™ – obstructive coronary artery disease diagnosis
- HART KD™ – Kawasaki disease diagnosis
HART test results have been peer-reviewed published 24 times, including at leading cardiovascular meetings—(European Society of Cardiology Congress – 2016, 2018, 2021; American College of Cardiology Scientific Sessions – 2017, 2018, 2019 (2), 2020, 2021; American Heart Association Scientific Sessions – 2017, 2018, 2019; American Diabetes Association Scientific Sessions – 2018, 2019; Pediatric Academic Societies International Sessions – 2021; International Spinal Cord Society Scientific Sessions – Oct 2021) and in top-tier journals—(Journal of American College of Cardiology – Mar 2017; American Journal of Cardiology – July 2017; Clinical Cardiology – June 2018; Open Heart – November 2018, May 2019; Jan 2019; Biomarkers in Medicine – June 2020; Journal of American Heart Association – Aug 2020).
About Prevencio, Inc.:
Prevencio's value proposition is "Preventing the Preventable” — That is, preventing unnecessary procedures, related side effects, and expense, as well as improving patient outcomes and clinical trials through more accurate blood tests for Cardiovascular Disease conditions. Prevencio utilizes Machine Learning (Artificial Intelligence) + Multi-Proteomic Biomarkers + Proprietary Algorithms to deliver cardiovascular diagnostic & prognostic tests that are significantly more accurate than standard-of-care stress tests. The Company is headquartered in Kirkland, Washington. For additional information, visit Prevencio, Inc.
Forward-Looking (Safe Harbor) Statement:
Except for historical and factual information contained herein, this press release contains forward-looking statements, such as market need, acceptance, and size, the accuracy of which is necessarily subject to various uncertainties of development-stage companies. The Company does not undertake to update disclosures contained in this press release.
